MagForce NT GmbH
Berlin
About MagForce NT GmbH
MagForce is forging new paths to treat cancer successfully and gently. With NanoTherm® Therapy System (NTTS), we have developed an innovative approach based on nanotechnology, which we want to make available to patients worldwide. And we are getting closer and closer to this goal. NTTS is the first and only nanotechnology-based therapy with European approval for treating recurrent Glioblastoma, a deadly brain tumor. To date, many patients diagnosed with Glioblastoma tumors have improved their quality of life after using our technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $24.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jun 2022)
- Ticker: fra:MF6G
- Website: magforce.de
- Phone: +49 30 3083800
Industries & Categories
Health Care, Medical Device, Nanotechnology, Oncology
Social Profiles
Canonical: https://fsome.com/organization/magforce-nt-gmbh-197843 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.